Proprietary Product Pipeline

Juniper Pharmaceuticals is developing therapeutics that address unmet medical needs in women’s health.

We have a successful heritage in developing pharmaceutical products, including CRINONE® 8% (progesterone gel), which is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and Allergan, Inc. in the U.S.

We are uniquely positioned to leverage pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities of Juniper Pharma Services to advance our proprietary therapeutics while also providing valuable intellectual property-related consultative and clinical trial manufacturing services to our pharmaceutical industry customers.

Our current product pipeline is focused on candidates that employ our proprietary intravaginal ring (IVR) technology for targeted delivery of pharmaceuticals.

These candidates leverage the 505(b)(2) pathway; initial human clinical trials are expected to begin at Phase 2.

We are actively evaluating additional pharmaceutical products for both internal development and potential collaborations. These candidates will be announced as they clear internal development hurdles including filings with the U.S. Patent and Trademark Office, commercial assessments, and clinical development and regulatory planning.

With a highly experienced leadership team, a strong balance sheet and positive cash flows from our core business, all of which support the development of our product pipeline, we are well positioned for continued success.